Upcoming event
EAU UROonco: A meeting steered by the EAU Section of Oncological Urology (ESOU)
Back

KEYNOTE-426 study

2023-06-03


Dr. Rini elaborates on the results of the KEYNOTE-426 study: Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced ccRCC.